<DOC>
	<DOCNO>NCT01582282</DOCNO>
	<brief_summary>A double-blind , randomize , placebo-controlled , multi-dose clinical study consist 2 phase ; 1 ) 8-week lead-in period patient follow diet judged within acceptable guideline ADA , 2 ) 12-week treatment period , begin , Subjects randomly assign 1 3 treatment group : placebo , 3.4 g psyllium BID total 6.8 g/day ( 10.4g Metamucil ) 6.8g psyllium BID total 13.6 g/day ( 20.8g Metamucil ) . For 12 week , Subjects take Metamucil fiber-free placebo BID , prior breakfast dinner . Patients visit clinic 10 time 20-week period Screening , Weeks -8 , -6 , -4 , 0 , Day 3 , Weeks 2 , 4 , 8 12 , fast least 12 hour prior visit blood sample take ( visit except Week -6 Day 3 ) analysis fast serum glucose lipid level , HbA1c . Clinical chemistry , hematology urinalysis do Weeks -8 , 0 12 . The complete 7-day food diary review study dietician visit discuss patient ensure compliance recommend diet patient ' body weight record</brief_summary>
	<brief_title>Study Metamucil Blood Glucose HbA1c Type II NIDDM Subjects</brief_title>
	<detailed_description>During first phase , lead-in period Subjects follow diet judged within acceptable guideline ADA , compliance assess study dietician use 7-day food diary complete patient . Subject body weight , serum glucose serum HbA1c , lipid level allow stabilize period . During 12-week treatment period , Subjects stratify either diet alone diet oral hypoglycemic medication randomly assign 1 3 treatment group : placebo , 3.4 g psyllium BID total 6.8 g/day ( 10.4g Metamucil ) 6.8g psyllium BID total 13.6 g/day ( 20.8g Metamucil ) . For 12 week , patient take Metamucil fiber-free placebo BID , prior breakfast dinner . Patients visit clinic 10 time 20-week period Screening , Weeks -8 , -6 , -4 , 0 , Day 3 , Weeks 2 , 4 , 8 12 , fast least 12 hour prior visit blood sample take ( visit except Week -6 Day 3 ) analysis fast serum glucose lipid level , HbA1c . Clinical chemistry , hematology urinalysis do Weeks -8 , 0 12 . The complete 7-day food diary review study dietician visit discuss patient ensure compliance recommend diet patient ' body weight record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>Have clinical diagnosis Type II diabetes mellitus , control diet and/or second generation oral hypoglycemic drug , onset disease age 35 . Are 0 50 % `` normal '' body weight ( adjust frame ) accord Metropolitan Life Insurance Tables . Are male female , age 3680 year diagnosis make least 1 year prior enrollment . Have HbA1c level 6 10 % Have fast serum glucose level 120220 mg/dL vary ±20 % month prior enter treatment phase HbA1c level vary ±10 % month prior enter treatment phase . Serum glucose level must 120220mg/dl subject 's HbA1c 6 10 % Week 0 . Have `` stable '' diet consistent ADArecommended dietary guideline intake total dietary fiber &lt; 15g/1000 calorie willing maintain diet 20week study . Have maintain constant body weight ( ±5 % ) month prior enter treatment phase Have condition would interfere evaluation</criteria>
	<gender>All</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Type II NIDDM</keyword>
</DOC>